Explore / Clinical trial
Clinical trial

Assessment of Abuse Potential of Rapastinel in Humans

Naurex, Inc, an affiliate of Allergan plcCompletedPhase 1Started Nov 1, 201872 enrolledUnited StatesNCT03799900

Abstract

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Ketamine

Keywords

Human Abuse Potential

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.